Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Perioperative outcomes

From: Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer

VariablesTotal patients (n=22)
Peritoneal cancer index (PCI)* 
 <107 (31.8)
 10-1911 (50.0)
 ≥204 (18.2)
 Mean PCI12.0 ± 7.9 (0-26)
 Median PCI ‡‡13 (3-17)
Completeness of cytoreduction (CC) 
 CC-022 (100)
 CC-10
Total operative time, hour11.4 ± 2.6 (7.5-16.5)
Operative time for concurrent liver surgery, hour3.0 ± 2.5 (0.5-9.0)
Estimated blood loss, mL1418.6 ± 1204.1 (250-5000)
Intraoperative transfusion, mL475.4 ± 740.4 (0-3030)
Postoperative laboratory findings 
 CEA , ng/mL2.6 (0.4-32.9)
 CA 19-9 , U/mL29.4 (4.1-232)
 Hemoglobin , g/dL10.6 (7.5-13.7)
 Albumin , g/dL2.7 (1.4-3.3)
 Total bilirubin , mg/dL1.3 (0.4-2.4)
 AST , IU/L170.5 (77-498)
 ALT , IU/L137 (30-440)
Length of ICU stay, days3.1 ± 7.9 (0-38)
Length of hospital stay, days25.6 ± 16.7 (9-71)
Numbers to treat adjuvant chemotherapy*21 (95.5)
Interval between surgery and adjuvant chemotherapy‡‡, days40.5 (31-63)
  1. *, n (%); , mean ± standard deviation (range); , median (range); ‡‡, median (quartile); AST aspartate aminotransferase; ALT alanine aminotransferase; ICU intensive care unit